# IB NEWS

**JUNE 2023 | EDITION #4**

ImagingBiometrics
an IQ-AI Company

CREATING THE STANDARD

PROVEN • AUTOMATED • QUANTITATIVE







**Dr. Jennifer Connelly and one of her clinical trial patients were recently interviewed in recognition of Brain Tumor Awareness month celebrated in May each year. *The interview can be viewed here.* Contact The Medical College of Wisconsin Cancer Center Clinical Trials Office at 414-805-8900, 866-680-0505, or by email at: cccto@mcw.edu.**

**The Imaging Biometrics team is grateful for the support they've received from the Chasing Chad organization.**

## Updates and Accolades

- Our most recent IB User's Group Webinar took place on April 11, 2023: "Clinical Advances of Perfusion MRI in the Current Neuro-oncology Landscape," presented by Dr. Michael Iv, MD. The presentation focused on the advanced application of IB Delta T1 maps (patent pending) and the quantitative DSC perfusion imaging capabilities available in IB Neuro. ***View here***

- Congratulations to Dr. Jennifer Connelly, MD, of The Medical College of Wisconsin (MCW), for having her abstract accepted at the 2023 SNO/ASCO CNS Cancer Conference. Dr. Connelly is leading our sponsored clinical trial, "A Phase 1 Study of Gallium Maltolate in Patients with Recurrent Glioblastoma (GBM)." The trial has strong momentum, the results so far are encouraging, and planning for Phase 2 is already underway.

- Drs. Joseph Bovi and Jennifer Connelly recently had the honor of hosting Chasing Chad, an organization that supports brain tumor research, and they are deeply appreciative of the support that Chasing Chad has given to our research team, as well as to patients and their families, for more than a decade.

- Imaging Biometrics assisted in "Transforming the Future" by exhibiting at this year's American Society of Neuroradiology annual meeting in Chicago. Kathleen Schmainda, PhD, delivered an informative and insightful presentation titled "State of the Art MR Perfusion Imaging in Brain Tumors."

- Jay Urbain, PhD, also presented at the ASNR meeting. His presentation, entitled "Randomized dropout of brain MR input series increases model flexibility, generalizability, and performance," addressed ways to overcome some of the issues commonly associated with artificial intelligence (AI) deep learning modeling. Dr. Urbain is actively working to further advance IB's integration of AI into its products and services.

- We are pleased to announce that Imaging Biometrics has partnered with Prism Clinical Imaging ***(View here)***, making available a suite of the most advanced fMRI, DTI, and MR perfusion applications for comprehensive brain mapping and surgical planning.

- IB is excited to share news of the launch of Neuro Suite, TeraRecon's AI-powered clinical suite which streamlines decision-making for chronic neurological care across healthcare organizations. Several IB tools provide key capabilities in Neuro Suite. ***Read the announcement here.***

# IB NEWS

ImagingBiometrics
an IQ-AI Company

## IB'S QUANTITATIVE IMAGING NOW AVAILABLE AS A SERVICE!

We are pleased to announce a new service model in which we process studies for clients, so they don't have to! The processing is performed entirely behind the client's firewall, ensuring patient data never leaves the client system. In addition to dealing with any manual processing tasks, we provide a longitudinal report which captures the full capabilities of IB's exclusive quantitative mapping technologies. Using Delta T1 (dT1) and standardized rCBV (sRCBV) parameter maps, IB can create quantitative class maps, displaying regions of low (blue), mid (yellow), and high (red) levels of sRCBV within the enhancing region on a post-contrast T1 series (T1+C). Studies have correlated spatially matched tissue samples with sRCBV output, helping to answer one of the most crucial questions in neuro-oncology today: Does the enhancing region on a T1+C indicate the presence of high-grade brain tumor or the effect of treatment?

**Patient treated with radiation therapy. Surgical diagnosis confirmed profound treatment effect. No tumor seen.**




**Longitudinal Reporting**




## Being Deployed

IB NIMBLE

Our development team is transforming IB Nimble so it can easily incorporate protocols for diseases beyond metastatic brain tumors. The handheld mobile app is used to facilitate secure, virtual, and real-time discussions among multi-disciplinary treatment teams. The countdown is on for deploying IB Nimble in an entirely new disease site. Great work by the development team! If you would like to learn how IB Nimble can be used at your institution, please contact *info@imagingbiometrics.com*

**Interested in evaluating Imaging Biometrics' quantitative mapping solutions, but not sure how to get started? Let the experts at IB help!**

**CONTACT US AT:**

**info@imagingbiometrics.com**
**or 262-439-8252**

**EMPLOYEE SPOTLIGHT**

## Meet Mike Schmainda

Mike is a co-founder of IB and serves as its CEO. Originally from a small town in central Minnesota, his marital path brought him to Wisconsin where he maintains a strong allegiance to the Minnesota Vikings (despite living in Packer country). Outside of work he enjoys spending time with family, everything outdoors, and coaching various sports at the youth and high school levels.

## IB USER'S GROUP

**On September 19, 2023, at noon CDT,**

Josh McComack will present a webinar titled, "Integrating IB Clinic in Routine Clinical Workflows." Josh is a Senior Software Engineer for Imaging Biometrics. Stay tuned for registration information.

FOLLOW US ON

https://twitter.com/iqai_ib
https://www.linkedin.com/company/imaging-biometrics-llc

13416 Watertown Plank Road
Suite 260 | Elm Grove, WI 53122
+1.262.439.8252